SAN DIEGO, March 4, 2024 /PRNewswire/ -- Amprion is pleased to announce its presence at the AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders in Lisbon, Portugal on March 5-9. Amprion's αSyn seed amplification assay (αS-SAA), commercially known as the SYNTap ® Biomarker Test, has been utilized in several studies, the results of which will be shared throughout 10 posters and oral presentations during the conference.
"We look forward to sharing findings from research sites around the world related to the accurate diagnosis of neurological disorders, made possible by Amprion's αSyn seed amplification assay," said Russell Lebovitz, MD, Ph.D., Amprion CEO & Cofounder. "AD/PD ™ provides an opportunity to discuss how αS-SAA is helping to improve the diagnosis and treatment of neurodegenerative diseases such as Alzheimer's, Parkinson's, and dementia with Lewy bodies, among others. Amprion is in the process of growing its team, beginning with diagnostics service consultants, to better serve clinical needs in the United States and support researchers and biopharmaceutical companies developing life-saving drugs for patients suffering from these diseases." Below are details of the posters and oral presentations highlighting findings related to SYNTap
Presenting Author: Luis Concha-Marambio, PhD, Amprion Location: Auditorium VIII
Lecture Title: Alpha-Synuclein Seed Amplification Assay (SAA) Performance in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Cohort Showing Extensive Comorbid Lewy Body Pathology Lecture Time: 15:45-16:00
Lecture Time: 16:00-16:15
Session Title: α-Synucleinopathies: Mechanisms, Pathophysiology and Modelling of Progression
Location: Auditorium VIII
Lecture Title: A Biological Definition and Research Integrated Staging System of Neuronal α -Synuclein Disease: Staging of the PPMI Cohort Lecture Time: 14:25-14:40
Session Title: PD and PSP: Advances in Diagnosis and Drug Development
Location: Auditorium VIII
Presenter: Jean-Cosme Dodart, PhD, Vaxxinity
Lecture Time: 18:00-18:15
"The data presented on the ADNI cohort at AD/PD™ will demonstrate the potential of using a-synuclein CSF SAA as a reliable assay for detecting co-morbid Lewy Body pathology, as well as its ability to identify this often-elusive co-pathology," said Mike Weiner, MD, and principal investigator for the Alzheimer's Disease Neuroimaging Initiative. "We believe the results will have profound implications for improving the accuracy of diagnosis, ultimately enabling the development of precision medicines for these complex neurodegenerative diseases." An additional study including data from Amprion's αS-SAA will be presented by Biogen. Details regarding the presentation are included below: Session Title: α-Synucleinopathies: Mechanisms, Pathophysiology and Modelling of Progression 01
Lecture Time: 18:55-19:10
Those interested in learning more about how the SYNTap
® Biomarker Test acts as the missing puzzle piece for completing the neurodegenerative disease diagnostic picture may visit Booth #62 for more information. For more information, visit https://ampriondx.com/ or find us on LinkedIn.